Notice of Intent to Publish a Funding Opportunity Announcement for Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
ID: 351610Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351610
Timeline
  1. 1
    Forecast Posted Jan 26, 2024 12:00 AM
  2. 2
    Forecast Due Jun 14, 2024 12:00 AM
  3. 3
    Posted Dec 21, 2023 12:00 AM
  4. 4
    Due Not available
Description

The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed). This initiative aims to support the TrialNet Clinical Network Hub (HUB), which serves as a coordination unit for clinical trials focused on preventing and intervening early in type 1 diabetes (T1D). The HUB's main objective is to enhance the efficiency and productivity of the TrialNet network by coordinating communications and outreach, developing new tools and approaches for screening, recruitment, and retention. The funding opportunity will require applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) as part of the scientific and technical peer review evaluation. Failure to include a PEDP will result in the application being considered incomplete and withdrawn. The funding opportunity is expected to be published in Spring 2024, with an application due date in Summer 2024. The funding instrument type for this opportunity is a Cooperative Agreement, and the estimated total program funding is $1,000,000.

Point(s) of Contact
No information provided.
Files
No associated files provided.
Similar Opportunities
Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the TrialNet Coordinating Center (TNCC), which is part of the TrialNet network. The TNCC plays a crucial role in identifying individuals with type 1 diabetes (T1D) at different stages of the disease and enrolling them in trials and studies aimed at preventing the progression of clinical symptoms and preserving insulin production. The TNCC supports various research projects, manages data and samples, and oversees network administration and operations. The TNCC will also be responsible for evaluating, selecting, and funding Clinical Centers and central support units necessary for TrialNet's clinical studies. The TNCC PD/PI will be a voting member of the TrialNet Executive and Steering Committees. The funding opportunity announcement is expected to be published in Spring 2024, with an application due date in Summer 2024. The TNCC will be funded through a cooperative agreement, and the estimated total program funding is $29,500,000.
Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)". This grant aims to provide support for the TrialNet Coordinating Center (TNCC), which plays a crucial role in identifying individuals with type 1 diabetes (T1D) and enrolling them in trials and studies focused on preventing disease progression and preserving insulin production. The TNCC will be responsible for various research projects at different stages of development, implementation, and completion. Additionally, it will handle data and sample management, including acquisition, quality control, dissemination, and public accessibility. The TNCC will also oversee network administration and operations, including the evaluation, selection, and funding of Clinical Centers and central support units. Applicants for this grant should include a Plan for Enhancing Diverse Perspectives (PEDP), which will be evaluated as part of the scientific and technical peer review process. Failure to include a PEDP will result in the application being considered incomplete and withdrawn. For more information and detailed instructions, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-004.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-004.html). If you have any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)". This funding opportunity falls under the category of Health and is a discretionary grant. The grant is a cooperative agreement and does not require cost sharing or matching. The deadline for applications is October 24, 2024. The purpose of this grant is to provide funding for the continuation of the Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D). The University of Pennsylvania has been identified as the recipient of this single source cooperative agreement. The program aims to identify, collect, and characterize primary pancreatic tissues and immune cells from patients with type 1 diabetes (T1D) or at risk of developing the disease, as well as age-matched controls. The collected data will be analyzed, organized, and shared through the existing PANC DB open-access resource database. The program is part of the Human Islet Research Network (HIRN), which focuses on understanding the loss of human beta cells in T1D and finding strategies to protect and replace functional human beta cell mass. Small businesses and other eligible applicants are invited to apply for this grant opportunity. Non-domestic (non-U.S.) entities and components of U.S. organizations are not eligible to apply. For more information on eligibility, please refer to the full Notice of Funding Opportunity. The maximum award ceiling for this grant is $5,500,000. For further details and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-012.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-012.html). If there are any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Notice of Intent to Publish a Notice of Funding Opportunity for Diabetes Research Centers (P30 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for Diabetes Research Centers (P30 Clinical Trial Optional). This initiative aims to solicit applications for research on diabetes, its complications, and related endocrine and metabolic diseases. The NOFO is expected to be published in Spring 2024, with an application due date in Summer 2024. The estimated total program funding is $7,500,000. The NOFO will utilize the P30 activity code. This opportunity falls under the category of Health and is a discretionary grant. The eligible applicants are others, and there is no cost sharing or matching requirement. The estimated synopsis post date is March 1, 2024, and the estimated synopsis close date is June 18, 2024. The estimated award date and project start date are both April 1, 2025.
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)". This cooperative agreement aims to support investigator-initiated, high-risk multi-center clinical trials that have the potential to change clinical practice and/or public health. The trials should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. The grant does not require cost sharing or matching. It falls under the category of funding activity related to health. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments, Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. However, non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. The grant opportunity requires the completion of planning activities prior to submission. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34). It is strongly encouraged to consult with NIDDK Scientific/Research staff before submitting either a U34 or U01 application. The deadline for application submission is November 5, 2026. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/pa-files/PAR-24-103.html](http://grants.nih.gov/grants/guide/pa-files/PAR-24-103.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.